Abbott expects the remaining company, centered on medical devices, diagnostics and established pharmaceuticals, to have approximately $42 billion in annual revenue. Nutrition will enter public markets with well-known brands, 16,000 employees and 14 manufacturing sites, but its future valuation will depend on more than brand recognition. Management already plans for Nutrition to incur debt and transfer part of the borrowing proceeds to Abbott; the division’s existing legal exposure has not yet been assigned between the two companies.
Nutrition’s recovery is uneven
The business Abbott intends to separate is large, but its recent results explain the appeal of a breakup. Nutrition generated $2.262 billion in third-quarter 2026 revenue, up 5.1% from the year-earlier quarter, according to Abbott’s October 21 earnings tables. Across the first nine months of 2026, however, sales were $6.423 billion, down 1.3% from the comparable 2025 period. The third-quarter improvement has not yet overcome a weaker first half, and Abbott cut its companywide 2026 comparable-sales-growth forecast to approximately 6% on the same day it announced the breakup.
| Nutrition measure | Reported 2026 result | Year-over-year change |
|---|---|---|
| Third-quarter sales | $2.262 billion | +5.1% |
| Third-quarter pediatric sales | $1.063 billion | +8.8% |
| Third-quarter adult sales | $1.199 billion | +2.0% |
| First-nine-month sales | $6.423 billion | -1.3% |
| First-nine-month U.S. sales | $2.673 billion | -4.5% |
Nutrition represented approximately 17.4% of Abbott’s $13.013 billion third-quarter sales, based on the company’s reported figures. Within Nutrition, pediatric products grew almost 9% during the quarter while adult products grew only 2%, leaving the two product groups with markedly different recent momentum. Abbott’s description of Nutrition as an approximately $8.5 billion annual business is a company estimate, not a disclosed standalone income statement.
On the third-quarter earnings call, CFO Philip Boudreau offered a more specific version of the investment thesis. Excluding Nutrition from today’s portfolio, management estimates Abbott’s sales growth would improve by 50 to 100 basis points, gross margin by more than 200 basis points and operating margin by approximately 100 basis points. These are management’s illustrative mix effects, not forecasts of what either company’s eventual standalone income statement will look like after corporate-cost allocations and separation expenses.
The new company is expected to borrow money
Abbott’s press release promises shareholders a distribution intended to qualify as tax-free for U.S. federal income tax purposes. Existing ABT owners would retain their Abbott shares and receive shares of Nutrition; no record date, distribution ratio, new company name or ticker has been announced. Daniel Salvadori, currently an Abbott executive vice president, is slated to become Nutrition’s chief executive.
The earnings call supplied an important detail absent from the headline transaction terms: Abbott expects the new Nutrition company to raise debt and distribute some of the proceeds back to its parent. Neither the borrowing amount nor the cash transfer has been set. The transaction therefore has two potential moving parts for Abbott shareholders: the value of the Nutrition shares they receive and the amount of leverage left inside those shares after the parent receives cash.
Abbott also expects the combined dividend from the two publicly traded companies to equal Abbott’s dividend at the time of separation. That is a promise about the total payment, not a commitment that each company will pay the old Abbott dividend independently or that the current $0.63 quarterly rate will remain unchanged until 2027. Investors will need the eventual payout allocation, debt terms and cash-flow disclosures to judge the sustainability of either distribution.
Who gets the infant-formula liabilities?
Litigation is the most consequential unresolved part of Nutrition’s proposed balance sheet. In August, Abbott agreed to pay approximately $670 million to resolve the Gill case and claims relating to its specialty formulas for preterm infants brought on behalf of approximately 2,000 other individuals. Abbott maintains that its products are safe and disputes allegations that the formulas cause necrotizing enterocolitis; the agreement does not resolve every outstanding claim.
Analysts asked Abbott directly on October 21 whether that litigation would remain with the parent. CEO Robert Ford did not assign the liabilities to either side, saying that the company would provide details as separation planning advances and that resolving all litigation is not a prerequisite to the spinoff. A promise to capitalize both businesses adequately does not establish which one ultimately bears the existing claims, future defense costs or indemnification obligations.
The eventual Form 10 should clarify the distribution of liabilities, any cross-company indemnities and the debt-funded cash payment to Abbott. Until then, a comparison of Nutrition with other publicly traded food, beverage or healthcare-products companies would be missing crucial inputs: the claims and financing obligations against the business. A familiar portfolio of brands is an insufficient substitute for those numbers.
Abbott has run this playbook twice before
In April 2004, Abbott distributed one Hospira share for every ten Abbott shares, separating its hospital-products operations into an independent company. Pfizer ($PFE) acquired Hospira in 2015 for $90 per share in cash. In January 2013, Abbott completed its separation of AbbVie, distributing one ABBV share for each Abbott share and putting its research-based pharmaceutical business into a separately traded company.
Those transactions show a repeat willingness to carve apart businesses with different economics. Hospira subsequently became an acquisition target, while AbbVie developed as a large independent drugmaker; neither precedent supplies a valuation for Nutrition or determines who will carry the formula litigation. Investors following Abbott’s proposal can track it alongside other announced separations in our Upcoming Spinoffs calendar, including Johnson & Johnson’s planned DePuy Synthes separation.
Abbott has targeted completion by the end of 2027 and expects a Form 10 registration statement before the transaction can proceed. The most useful disclosures will be Nutrition’s standalone earnings and cash flow, the opening debt balance, the amount Abbott receives, the division of legal liabilities and the proposed share-distribution ratio. Without those details, the announced $8.5 billion in sales describes the business’s scale, but not the equity value Abbott shareholders will receive.